Igor C. Almeida to Chagas Disease
This is a "connection" page, showing publications Igor C. Almeida has written about Chagas Disease.
Connection Strength
4.808
-
Alonso-Vega C, Urbina JA, Sanz S, Pinazo MJ, Pinto JJ, Gonzalez VR, Rojas G, Ortiz L, Garcia W, Lozano D, Soy D, Maldonado RA, Nagarkatti R, Debrabant A, Schijman A, Thomas MC, L?pez MC, Michael K, Ribeiro I, Gascon J, Torrico F, Almeida IC. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. BMJ Open. 2021 12 31; 11(12):e052897.
Score: 0.752
-
Ortega-Rodriguez U, Portillo S, Ashmus RA, Duran JA, Schocker NS, Iniguez E, Montoya AL, Zepeda BG, Olivas JJ, Karimi NH, Alonso-Padilla J, Izquierdo L, Pinazo MJ, de Noya BA, Noya O, Maldonado RA, Torrico F, Gascon J, Michael K, Almeida IC. Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of a-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas Disease. Methods Mol Biol. 2019; 1955:287-308.
Score: 0.611
-
Andrade AL, Martelli CM, Oliveira RM, Silva SA, Aires AI, Soussumi LM, Covas DT, Silva LS, Andrade JG, Travassos LR, Almeida IC. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg. 2004 Nov; 71(5):594-7.
Score: 0.229
-
Pagura L, Dumoulin PC, Ellis CC, Mendes MT, Estevao IL, Almeida IC, Burleigh BA. Fatty acid elongases 1-3 have distinct roles in mitochondrial function, growth, and lipid homeostasis in Trypanosoma cruzi. J Biol Chem. 2023 06; 299(6):104715.
Score: 0.205
-
Silva Grij? Farani P, Iandra da Silva Ferreira B, Begum K, Vilar-Pereira G, Pereira IR, Fern?ndez-Figueroa EA, Cardenas-Ovando RA, Almeida IC, Roy S, Lannes-Vieira J, Moreira OC. Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy. PLoS Negl Trop Dis. 2023 03; 17(3):e0011223.
Score: 0.205
-
Montoya AL, Carvajal EG, Ortega-Rodriguez U, Estevao IL, Ashmus RA, Jankuru SR, Portillo S, Ellis CC, Knight CD, Alonso-Padilla J, Izquierdo L, Pinazo MJ, Gascon J, Suarez V, Watts DM, Malo IR, Ramsey JM, Alarc?n De Noya B, Noya O, Almeida IC, Michael K. A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease. Molecules. 2022 Sep 05; 27(17).
Score: 0.197
-
Montoya AL, Gil ER, Heydemann EL, Estevao IL, Luna BE, Ellis CC, Jankuru SR, Alarc?n de Noya B, Noya O, Zago MP, Almeida IC, Michael K. Specific Recognition of ?-Galactofuranose-Containing Glycans of Synthetic Neoglycoproteins by Sera of Chronic Chagas Disease Patients. Molecules. 2022 Jan 09; 27(2).
Score: 0.188
-
Farani PSG, Begum K, Vilar-Pereira G, Pereira IR, Almeida IC, Roy S, Lannes-Vieira J, Moreira OC. Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy. Front Cell Infect Microbiol. 2021; 11:692655.
Score: 0.182
-
Torrico F, Gasc?n J, Barreira F, Blum B, Almeida IC, Alonso-Vega C, Barboza T, Bilbe G, Correia E, Garcia W, Ortiz L, Parrado R, Ramirez JC, Ribeiro I, Strub-Wourgaft N, Vaillant M, Sosa-Estani S. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021 08; 21(8):1129-1140.
Score: 0.179
-
Cortes-Serra N, Mendes MT, Mazagatos C, Segui-Barber J, Ellis CC, Ballart C, Garcia-Alvarez A, G?llego M, Gascon J, Almeida IC, Pinazo MJ, Fernandez-Becerra C. Plasma-Derived Extracellular Vesicles as Potential Biomarkers in Heart Transplant Patient with Chronic Chagas Disease. Emerg Infect Dis. 2020 08; 26(8):1846-1851.
Score: 0.170
-
Alonso-Padilla J, Abril M, Alarc?n de Noya B, Almeida IC, Angheben A, Araujo Jorge T, Chatelain E, Esteva M, Gasc?n J, Grijalva MJ, Guhl F, Hasslocher-Moreno AM, L?pez MC, Luquetti A, Noya O, Pinazo MJ, Ramsey JM, Ribeiro I, Ruiz AM, Schijman AG, Sosa-Estani S, Thomas MC, Torrico F, Zrein M, Picado A. Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus. PLoS Negl Trop Dis. 2020 04; 14(4):e0008035.
Score: 0.167
-
Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018 04; 18(4):419-430.
Score: 0.143
-
Brito CR, McKay CS, Azevedo MA, Santos LC, Venuto AP, Nunes DF, D'?vila DA, Rodrigues da Cunha GM, Almeida IC, Gazzinelli RT, Galv?o LM, Chiari E, Sanhueza CA, Finn MG, Marques AF. Virus-like Particle Display of the a-Gal Epitope for the Diagnostic Assessment of Chagas Disease. ACS Infect Dis. 2016 12 09; 2(12):917-922.
Score: 0.131
-
Schocker NS, Portillo S, Brito CR, Marques AF, Almeida IC, Michael K. Synthesis of Gala(1,3)Gal?(1,4)GlcNAca-, Gal?(1,4)GlcNAca- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease. Glycobiology. 2016 Jan; 26(1):39-50.
Score: 0.122
-
Pinazo MJ, Thomas MC, Bustamante J, Almeida IC, Lopez MC, Gascon J. Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz. 2015 May; 110(3):422-32.
Score: 0.118
-
Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, Maldonado RA. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease. Vaccine. 2014 Jun 12; 32(28):3525-32.
Score: 0.110
-
Zanforlin T, Bayer-Santos E, Cortez C, Almeida IC, Yoshida N, da Silveira JF. Molecular characterization of Trypanosoma cruzi SAP proteins with host-cell lysosome exocytosis-inducing activity required for parasite invasion. PLoS One. 2013; 8(12):e83864.
Score: 0.108
-
Izquierdo L, Marques AF, G?llego M, Sanz S, Tebar S, Riera C, Quint? L, Aldasoro E, Almeida IC, Gascon J. Evaluation of a chemiluminescent enzyme-linked immunosorbent assay for the diagnosis of Trypanosoma cruzi infection in a nonendemic setting. Mem Inst Oswaldo Cruz. 2013 Nov; 108(7):928-31.
Score: 0.107
-
Ashmus RA, Schocker NS, Cordero-Mendoza Y, Marques AF, Monroy EY, Pardo A, Izquierdo L, G?llego M, Gascon J, Almeida IC, Michael K. Potential use of synthetic a-galactosyl-containing glycotopes of the parasite Trypanosoma cruzi as diagnostic antigens for Chagas disease. Org Biomol Chem. 2013 Sep 14; 11(34):5579-83.
Score: 0.106
-
Nakayasu ES, Sobreira TJ, Torres R, Ganiko L, Oliveira PS, Marques AF, Almeida IC. Improved proteomic approach for the discovery of potential vaccine targets in Trypanosoma cruzi. J Proteome Res. 2012 Jan 01; 11(1):237-46.
Score: 0.094
-
De Marchi CR, Di Noia JM, Frasch AC, Amato Neto V, Almeida IC, Buscaglia CA. Evaluation of a recombinant Trypanosoma cruzi mucin-like antigen for serodiagnosis of Chagas' disease. Clin Vaccine Immunol. 2011 Nov; 18(11):1850-5.
Score: 0.092
-
Bussacos AC, Nakayasu ES, Hecht MM, Parente JA, Soares CM, Teixeira AR, Almeida IC. Diversity of anti-haemostatic proteins in the salivary glands of Rhodnius species transmitters of Chagas disease in the greater Amazon. J Proteomics. 2011 Aug 24; 74(9):1664-72.
Score: 0.091
-
Genovesio A, Giardini MA, Kwon YJ, de Macedo Dossin F, Choi SY, Kim NY, Kim HC, Jung SY, Schenkman S, Almeida IC, Emans N, Freitas-Junior LH. Visual genome-wide RNAi screening to identify human host factors required for Trypanosoma cruzi infection. PLoS One. 2011; 6(5):e19733.
Score: 0.090
-
Furuch? CR, Umezawa ES, Almeida I, Freitas VL, Bezerra R, Nunes EV, Sanches MC, Guastini CM, Teixeira AR, Shikanai-Yasuda MA. Inconclusive results in conventional serological screening for Chagas' disease in blood banks: evaluation of cellular and humoral response. Trop Med Int Health. 2008 Dec; 13(12):1527-33.
Score: 0.075
-
Mesquita RD, Carneiro AB, Bafica A, Gazos-Lopes F, Takiya CM, Souto-Padron T, Vieira DP, Ferreira-Pereira A, Almeida IC, Figueiredo RT, Porto BN, Bozza MT, Gra?a-Souza AV, Lopes AH, Atella GC, Silva-Neto MA. Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine. Infect Immun. 2008 Dec; 76(12):5543-52.
Score: 0.075
-
Monteiro AC, Schmitz V, Svensjo E, Gazzinelli RT, Almeida IC, Todorov A, de Arruda LB, Torrecilhas AC, Pesquero JB, Morrot A, Bouskela E, Bonomo A, Lima AP, M?ller-Esterl W, Scharfstein J. Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi. J Immunol. 2006 Nov 01; 177(9):6325-35.
Score: 0.066
-
Maldonado RA, Kuniyoshi RK, Linss JG, Almeida IC. Trypanosoma cruzi oleate desaturase: molecular characterization and comparative analysis in other trypanosomatids. J Parasitol. 2006 Oct; 92(5):1064-74.
Score: 0.065
-
Buscaglia CA, Campo VA, Di Noia JM, Torrecilhas AC, De Marchi CR, Ferguson MA, Frasch AC, Almeida IC. The surface coat of the mammal-dwelling infective trypomastigote stage of Trypanosoma cruzi is formed by highly diverse immunogenic mucins. J Biol Chem. 2004 Apr 16; 279(16):15860-9.
Score: 0.054
-
Di Noia JM, Buscaglia CA, De Marchi CR, Almeida IC, Frasch AC. A Trypanosoma cruzi small surface molecule provides the first immunological evidence that Chagas' disease is due to a single parasite lineage. J Exp Med. 2002 Feb 18; 195(4):401-13.
Score: 0.047
-
Nogueira NF, Gonzalez MS, Gomes JE, de Souza W, Garcia ES, Azambuja P, Nohara LL, Almeida IC, Zingales B, Colli W. Trypanosoma cruzi: involvement of glycoinositolphospholipids in the attachment to the luminal midgut surface of Rhodnius prolixus. Exp Parasitol. 2007 Jun; 116(2):120-8.
Score: 0.017
-
Proc?pio DO, Almeida IC, Torrecilhas AC, Cardoso JE, Teyton L, Travassos LR, Bendelac A, Gazzinelli RT. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. J Immunol. 2002 Oct 01; 169(7):3926-33.
Score: 0.012